Tenderwize
Retour à la recherche

Open-House discount agreements for Eribulin

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Aug 21, 2027 · 360 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Open-House Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Eribulin, ATC L01XX41 - Vertragsregionen Niedersachsen, Bremen und Sachsen-Anhalt

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The notice requires handwritten signatures on paper originals, while only the separate file is sent by email. Missing t...

Eligibility is limited to pharmaceutical undertakings under the AMG, or a consortium of such undertakings, and local re...

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Supply-related Open-House discount agreements for the active substance Eribulin (ATC L01XX41).
  • Applies to parenteral preparations from finished medicinal products used in oncology for immediate physician administration.
Afficher le résumé complet

Open-House framework-style pharmaceutical supply arrangement for Eribulin (ATC L01XX41) in Germany, covering the regions Niedersachsen/Bremen and Sachsen-Anhalt. The notice states that identical, non-exclusive discount agreements will be offered to all interested pharmaceutical companies that meet the stated eligibility conditions. Electronic submission is not allowed; signed paper originals and a separate file must be submitted. No contract value is stated.

Risques

The notice requires handwritten signatures on paper originals, while only the separate file is sent by email. Missing t...

Eligibility is limited to pharmaceutical undertakings under the AMG, or a consortium of such undertakings, and local re...

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG, or a consortium of pharmaceutical undertakings, for the offered medicinal products.
  • The company must have its seat in Germany, another EU Member State, or another EEA State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical undertakings for the offered products.

Critères d'attribution

Lot 1

Price criterion stated, but no weight or further detail provided.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Open-House discount agreements for Eribulin

Open-House non-exclusive discount agreements for Eribulin, ATC L01XX41, for parenteral preparations used in oncology for immediate physician administration. The notice says the agreements are offered for two regional lots: Lot 1 Niedersachsen/Bremen and Lot 2 Sachsen-Anhalt. Lot-specific value, CPV, and deadline details are not separately provided in the structured data.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Oct 2025 - Oct 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline Aug 21, 2027

Détails de la procédure

Date de publication
02 Sep 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
573935-2025

Appels d'offres similaires